東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Linked to FindBook

Google Book

Amazon

博客來

Experimental Evidence for a C-Peptide Complex Receptor on Red Blood Cells.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Experimental Evidence for a C-Peptide Complex Receptor on Red Blood Cells./
Author:	Geiger, Morgan.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
Description:	187 p.
Notes:	Source: Dissertations Abstracts International, Volume: 82-11, Section: B.
Contained By:	Dissertations Abstracts International82-11B.
Subject:	Chemistry. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28418659
ISBN:	9798728272533

Experimental Evidence for a C-Peptide Complex Receptor on Red Blood Cells.
Geiger, Morgan.

Experimental Evidence for a C-Peptide Complex Receptor on Red Blood Cells. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 187 p.

Source: Dissertations Abstracts International, Volume: 82-11, Section: B.

Thesis (Ph.D.)--Michigan State University, 2021.

This item must not be sold to any third party vendors.

Pancreatic β-cells secrete insulin and C-peptide, a 31-amino acid peptide, in a 1:1 mole ratio. People with type 1 diabetes (T1D) require exogenous insulin to survive due to damaged or destroyed β-cells. However, even with regular insulin treatments, patients develop complications such as retinopathy, neuropathy, and nephropathy, and it has been proposed that poor blood flow could be causing these complications. Prior research has shown that C peptide increases microvascular blood flow, therefore, it could be a useful therapy to prevent these complications. The unknown C peptide receptor and mechanism has been a major roadblock in utilizing C-peptide as a therapeutic. Our group has reported that approximately 1,800 C peptide molecules bind per red blood cell (RBC) in the presence of albumin, while there was no detectable C-peptide binding per RBC without albumin. Thus, it is hypothesized here that C-peptide binds to RBCs through an albumin/C-peptide complex receptor, as opposed to binding to the RBC alone.The work in this dissertation focuses on analyzing the binding of bovine serum albumin (BSA) to RBCs using a radiolabeling method to attach technetium-99m (Tc99m) to BSA for gamma decay detection. A binding saturation experiment was conducted to examine the BSA specific binding to RBCs with and without C-peptide. The specific binding curves revealed that albumin saturates at 14,021 (±1,489) BSA molecules/RBC with a Kd of 1.14 (±0.07) x 10-7 M. Whereas, in the presence of C-peptide and Zn2+, albumin saturates at 16,695 (±1,479) BSA molecules/RBC with a Kd of 2.00 (±0.05) x 10-7 M. At saturation, the additional 2,700 BSA molecules/RBC in the presence of C-peptide and Zn2+ indicates that not only does an albumin receptor exist on RBCs, but also a separate receptor for an albumin/C peptide complex.Due to its role in the delivery of C-peptide, the molecular state of albumin may be critical. Albumin is more glycated in individuals with T1D in comparison to healthy controls. This dissertation utilizes the radiolabeling saturation experiment to analyze the effects of glycation on BSA binding to RBCs. Varying percentage of glycation (11-48%) were analyzed with and without C-peptide and Zn2+. As the glycation percentage increased, the number of BSA molecules binding per RBC increased; however, the difference between samples containing C-peptide to those without C-peptide decreased. In fact, at the higher glycation levels, there is more albumin binding in the absence of C peptide. Importantly, the amount of RBC C-peptide uptake decreased when carried by glycated BSA compared to normal BSA.Abnormal albumin delivery may not only be a determinant of disease in people with T1D. Albumin delivery of C-peptide was also examined in people with multiple sclerosis (MS, an autoimmune disease). When comparing BSA binding to MS RBCs to healthy control RBCs, more BSA molecules bound per MS RBC. Previous research in our lab has shown that MS RBCs binds more C peptide and release higher concentrations of ATP than healthy controls. This suggests that in unhealthy conditions, the albumin/C peptide/Zn2+ complex is binding differently than in healthy conditions, which results in abnormal downstream effects.

ISBN: 9798728272533Subjects--Topical Terms:

516420
Chemistry.
Subjects--Index Terms:

Albumin

Experimental Evidence for a C-Peptide Complex Receptor on Red Blood Cells.
LDR:04440nmm a2200397 4500 001 2346400
005 20230315102159.5
006 m o d
007 cr#unu||||||||
008 241004s2021 ||||||||||||||||| ||eng d
020 $a 9798728272533
035 $a (MiAaPQ)AAI28418659
035 $a AAI28418659
040 $a MiAaPQ $c MiAaPQ
100 1 $a Geiger, Morgan. $3 3685487
245 1 0 $a Experimental Evidence for a C-Peptide Complex Receptor on Red Blood Cells.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 187 p.
500 $a Source: Dissertations Abstracts International, Volume: 82-11, Section: B.
500 $a Advisor: Spence, Dana.
502 $a Thesis (Ph.D.)--Michigan State University, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Pancreatic β-cells secrete insulin and C-peptide, a 31-amino acid peptide, in a 1:1 mole ratio. People with type 1 diabetes (T1D) require exogenous insulin to survive due to damaged or destroyed β-cells. However, even with regular insulin treatments, patients develop complications such as retinopathy, neuropathy, and nephropathy, and it has been proposed that poor blood flow could be causing these complications. Prior research has shown that C peptide increases microvascular blood flow, therefore, it could be a useful therapy to prevent these complications. The unknown C peptide receptor and mechanism has been a major roadblock in utilizing C-peptide as a therapeutic. Our group has reported that approximately 1,800 C peptide molecules bind per red blood cell (RBC) in the presence of albumin, while there was no detectable C-peptide binding per RBC without albumin. Thus, it is hypothesized here that C-peptide binds to RBCs through an albumin/C-peptide complex receptor, as opposed to binding to the RBC alone.The work in this dissertation focuses on analyzing the binding of bovine serum albumin (BSA) to RBCs using a radiolabeling method to attach technetium-99m (Tc99m) to BSA for gamma decay detection. A binding saturation experiment was conducted to examine the BSA specific binding to RBCs with and without C-peptide. The specific binding curves revealed that albumin saturates at 14,021 (±1,489) BSA molecules/RBC with a Kd of 1.14 (±0.07) x 10-7 M. Whereas, in the presence of C-peptide and Zn2+, albumin saturates at 16,695 (±1,479) BSA molecules/RBC with a Kd of 2.00 (±0.05) x 10-7 M. At saturation, the additional 2,700 BSA molecules/RBC in the presence of C-peptide and Zn2+ indicates that not only does an albumin receptor exist on RBCs, but also a separate receptor for an albumin/C peptide complex.Due to its role in the delivery of C-peptide, the molecular state of albumin may be critical. Albumin is more glycated in individuals with T1D in comparison to healthy controls. This dissertation utilizes the radiolabeling saturation experiment to analyze the effects of glycation on BSA binding to RBCs. Varying percentage of glycation (11-48%) were analyzed with and without C-peptide and Zn2+. As the glycation percentage increased, the number of BSA molecules binding per RBC increased; however, the difference between samples containing C-peptide to those without C-peptide decreased. In fact, at the higher glycation levels, there is more albumin binding in the absence of C peptide. Importantly, the amount of RBC C-peptide uptake decreased when carried by glycated BSA compared to normal BSA.Abnormal albumin delivery may not only be a determinant of disease in people with T1D. Albumin delivery of C-peptide was also examined in people with multiple sclerosis (MS, an autoimmune disease). When comparing BSA binding to MS RBCs to healthy control RBCs, more BSA molecules bound per MS RBC. Previous research in our lab has shown that MS RBCs binds more C peptide and release higher concentrations of ATP than healthy controls. This suggests that in unhealthy conditions, the albumin/C peptide/Zn2+ complex is binding differently than in healthy conditions, which results in abnormal downstream effects.
590 $a School code: 0128.
650 4 $a Chemistry. $3 516420
650 4 $a Endocrinology. $3 610914
650 4 $a Molecular chemistry. $3 1071612
653 $a Albumin
653 $a C-peptide
653 $a Radiolabeling
653 $a Red Blood Cells
653 $a Type 1 diabetes
690 $a 0485
690 $a 0431
690 $a 0409
710 2 $a Michigan State University. $b Chemistry - Doctor of Philosophy. $3 2094041
773 0 $t Dissertations Abstracts International $g 82-11B.
790 $a 0128
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28418659